Treatment of patients with Hypoxemic respiratory failure (HRF) and Acute Respiratory Distress Syndrome (ARDS) is complex. Therapies that have been shown to save the lives of patients with HRF and ARDS are available but they are not always provided. To reduce practice variation and improve adherence to evidence-informed therapies, the investigators developed the Treatment of Hypoxemic Respiratory Failure and ARDS with Protection, Paralysis, and Proning (TheraPPP) Pathway. The overall objective of TheraPPP Pathway is to improve the quality of care for patients with HRF. Implementation of the pathway across Alberta will test the effectiveness and implementation of the TheraPPP Pathway.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
EFFECTIVENESS (primary clinical outcome) 28-day ventilator free days
Timeframe: 4 months (after the study post-intervention period)
IMPLEMENTATION (primary fidelity outcome) Composite Fidelity Score
Timeframe: 4 months (after the study post-intervention period)
ECONOMIC (primary economic outcome) Cost per ventilator free day saved
Timeframe: 4 months (after the study post-intervention period)